BTCC / BTCC Square / Global Cryptocurrency /
Tempus AI Contracts Surge Past $1.1 Billion as Pharma Giants Embrace AI Platform

Tempus AI Contracts Surge Past $1.1 Billion as Pharma Giants Embrace AI Platform

Published:
2026-01-12 09:41:01
12
2
BTCCSquare news:

Tempus AI’s contract value milestone reflects accelerating adoption by pharmaceutical heavyweights. The company secured 70+ data agreements in 2025 with AstraZeneca, GSK, and Merck driving growth.

Diagnostics revenue nearly doubled to $955 million, powered by a 111% year-over-year surge. Oncology testing volumes ROSE 26%, while hereditary testing jumped 29%.

Wall Street maintains a Moderate Buy rating with a $87 median price target—29.77% upside potential. The stock gained amid broader crypto market momentum, though no direct coin or exchange correlations were identified in this healthcare AI development.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.